the Treatment of Normal Pressure Hydrocephalus Secures $85 Million in Latest Series C Funding Round

the Treatment of Normal Pressure Hydrocephalus secured $85 million in its latest Series C, adding another data point to the Enterprise Software & SaaS funding market.

the Treatment of Normal Pressure Hydrocephalus Raises $85 million in Funding

the Treatment of Normal Pressure Hydrocephalus is a Enterprise Software company focused on Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus.

Investors Behind the Funding

The round was backed by undisclosed investors. Funding Intelligence tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

the Treatment of Normal Pressure Hydrocephalus operates in Enterprise Software & SaaS. the Treatment of Normal Pressure Hydrocephalus's Series C round shows investors still backing enterprise software companies with differentiated positioning. At $85M, the deal suggests selective but real demand for businesses that can turn product traction into durable scale.

Strategic Use of Funds

Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus

Looking Ahead

CereVasc, Inc. Announces Over-Subscribed $85 Million Series C Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus

Source reference: original announcement/article.